Background and aims To evaluate the risc of flares in SLE patients
Methods A prospective analytic study of SLE patients (SLICC, 2012 criteria) with a fallowed–up in 5 visits: baseline visit, month 3, month 5, month 9 and month 12 visit. At visits disease activity (SLEDAI, SLAM), SELENA/SLEDAI flare index and laboratory tests were assessed.
Results The study included 102 patients, 94,1% females, age±SD 42.4±13.3 (range 20–73) years, disease duration±SD 93.9±77.1 (range 0,1–228) months. During fallow–up, 55 flares were enregistered, including 11 severe, with a SLEDAI increase with 3–17 points. The incidence of flares was 0,53 patient/year, the for severe flares - 0,10 patient/year. To assess the risk of flares, potential risk factors were studied (Table 1).
The main risk factors were laboratory findings, while only active pulmonary involvement derived from SLAM and antiphospholipid syndrome, as clinical and laboratory variables, associated with the flares in SLE patients.
Conclusions In our study, the incidence of flare in a 12 moths period was 53,9%, including 10,8% of severe flares. We have determined that patients with high ERS, low Hb and lymphocytopenia are at risk for flares and antiphospholipid syndrome and pulmonary involvement were the main clinical risk factors in our cohort.
- © 2017, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.